 |
市場調查報告書
商品編碼
1767678
血管收縮素轉化酵素(ACE) 抑制劑市場（按藥物、適應症、給藥途徑、通路和地區分類）Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, By Indication, By Route of Administration, By Distribution Channel, and By Region |
||||||
價格
簡介目錄
血管收縮素轉化酵素(ACE) 抑制劑市場規模預計在 2025 年為 90.003 億美元，預計到 2032 年將達到 131.797 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 5.6%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年的市場規模 | 90.3億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期：2025-2032年 | 5.60% | 2032年價值預測 | 131.797億美元 |
血管收縮素轉化酵素（ACE）抑制劑是一類主要用於治療高血壓和心臟衰竭的藥物。它們透過阻斷一種稱為血管收縮素II的荷爾蒙的作用而起作用。血管收縮素II會使血管收縮並促進一種稱為醛固酮的激素的分泌，這會導致體內液體和鹽的儲存。 ACE抑制劑透過阻斷血管收縮素II的產生，減少體內滯留的液體量並降低血壓，從而放鬆和擴張血管。常用的ACE抑制劑包括Lisinopril，Enalapril和Ramipril。副作用包括乾咳，頭暈和腎臟損傷。服用ACE抑制劑的人應定期檢查以監測其腎功能和鉀水平。 ACE抑制劑在減輕血管收縮素II的作用和幫助血管放鬆和擴張方面起著至關重要的作用，同時還能調節液體儲存並大大有助於降低血壓。
市場動態
全球血管收縮素轉化酵素(ACE) 抑制劑市場的成長是由全球高血壓和心臟病的高盛行率所推動的。人體會產生四種稱為血管收縮素（an-gee-oh-ten-sin，羅馬數字表示類型名稱）的荷爾蒙。血管收縮素轉換酶 (ACE) 將血管緊張素 I 轉化為血管收縮素II，後者會產生各種生理效應。 ACE 抑制劑通常被建議使用，尤其用於治療心血管疾病和高血壓。 2019 年，超過 1,290 萬名聯邦醫療保險 (Medicare) D 部分用戶（約佔 D 部分受保受益人的 27%）使用了 ACE 抑制劑。 ACE 抑制劑確實會引起不良反應。大多數不良反應較為輕微，但也有少數情況危險，需要緊急醫療照護。
研究的主要特點
- 本報告對全球血管收縮素轉化酵素(ACE) 抑制劑市場進行了詳細分析，並提供了預測期 2025-2032 的市場規模（百萬美元）和年複合成長率（CAGR%），假設基準年為 2024 年。
- 它還強調了各個領域的潛在商機，並解釋了該市場的有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
- 全球血管收縮素轉化酵素(ACE) 抑制劑市場的主要企業根據公司亮點、產品系列、關鍵亮點、性能和策略等參數進行分析。
- 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
- 全球血管收縮素轉化酵素(ACE) 抑制劑市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過分析全球血管收縮素轉化酵素(ACE) 抑制劑市場中使用的各種策略矩陣來促進決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- 一致的機會圖（COM）
第3章市場動態、法規與趨勢分析
- 市場動態
- 驅動程式
- 高血壓盛行率不斷上升
- 不斷成長的研發活動
- 提高心血管健康意識
- 限制因素
- 專利到期日
- 副作用和安全問題
- 副作用和安全問題
- 機會
- 驅動程式
- 提高心血管健康意識
- 個人化醫療
- 聯合治療
- 影響分析
- 監管情景
- 產品發布/核准
- PEST分析
- 波特分析
- 併購場景
4. 全球血管收縮素轉化酵素(ACE) 抑制劑市場（依藥物分類），2020 年至 2032 年
- 介紹
- Benazepril
- Perindopril
- 曲福普利
- Captopril
- Enalapril
- Lisinopril
- 其他（Ramipril等）
5. 全球血管收縮素轉化酵素(ACE) 抑制劑市場（依適應症分類），2020 年至 2032 年
- 介紹
- 高血壓
- 冠狀動脈疾病
- 心臟衰竭
- 慢性腎臟病
- 硬皮症
- 其他（偏頭痛等）
6. 全球血管收縮素轉化酵素（ACE）抑制劑市場（依給藥途徑），2020-2032
- 介紹
- 口服
- 注射
7. 全球血管收縮素轉化酵素（ACE）抑制劑市場（依通路分類），2020-2032
- 介紹
- 醫院藥房
- 零售藥局
- 網路藥局
8. 全球血管收縮素轉化酵素（ACE）抑制劑市場（按地區），2020-2032
- 介紹
- 北美洲
- 美國
- 加拿大
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 東南亞國協
- 澳洲
- 韓國
- 其他亞太地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 中東和非洲
- 海灣合作理事會國家
- 以色列
- 北非
- 中部非洲
- 其他中東和非洲地區
第9章 競爭態勢
- Novartis AG
- Pfizer Inc.
- Merck & Co.
- AstraZeneca
- Sanofi
- Boehringer Ingelheim
- GlaxoSmithKline
- Lupin Limited
- Torrent Pharmaceuticals Ltd.
- Reddy's Laboratories Ltd.
- Mylan
第 10 章 章節
- 調查方法
- 關於出版商
簡介目錄
Product Code: CMI2746
Angiotensin Converting Enzymes (ACE) Inhibitors Market is estimated to be valued at USD 9,000.3 Mn in 2025 and is expected to reach USD 13,179.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 9,000.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.60% | 2032 Value Projection: | USD 13,179.7 Mn |
Angiotensin converting enzymes (ACE) inhibitors are a type of medication used primarily in the treatment of high blood pressure and heart failure. They work by blocking the action of a hormone called angiotensin II. Angiotensin II causes blood vessels to constrict and promotes the release of another hormone called aldosterone, which leads to water and salt retention in the body. By inhibiting the production of angiotensin II, ACE inhibitors help to relax and widen the blood vessels, reduce the amount of water retained by the body, and therefore lower blood pressure. Commonly prescribed ACE inhibitors include lisinopril, enalapril, and ramipril. Side effects can include dry cough, dizziness, and kidney problems. It is important for individuals taking ACE inhibitors to have regular check-ups to monitor their kidney function and potassium levels. ACE inhibitors play a pivotal role in mitigating the effects of angiotensin II, aiding in the relaxation and widening of blood vessels while regulating fluid retention, thus contributing significantly to blood pressure reduction.
Market Dynamics
The global angiotensin converting enzymes (ACE) inhibitors market's growth is driven by the high prevalence of hypertension and heart disease globally. The body produces four distinct forms of the hormone angiotensin (an-gee-oh-ten-sin; the types' names are Roman numerals). Angiotensin I is converted to angiotensin II by ACE, which has a variety of bodily consequences. ACE inhibitors are often recommended, particularly for cardiovascular diseases and high blood pressure. An ACE inhibitor was given to over 12.9 million Medicare Part D participants in 2019 (or roughly 27% of all beneficiaries with Part D coverage). It is true that ACE inhibitors can cause negative effects. Most of them are mild, but a few are dangerous and require emergency medical attention.
Key features of the study
- This report provides in-depth analysis of the global angiotensin converting enzymes (ACE) inhibitors market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Novartis AG, Pfizer Inc., Merck & Co., AstraZeneca, Sanofi, Boehringer Ingelheim, GlaxoSmithKline, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mylan and Other Prominent Players.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global angiotensin converting enzymes (ACE) inhibitors market.
Market Segmentation
- By Drugs
- Benazepril
- Perindopril
- Trandfolapril
- Captopril
- Enalapril
- Lisinopril
- Others (Ramipril, etc.)
- By Indication
- Hypertension
- Coronary Artery Disease
- Heart Failure
- Chronic Kidney Disease
- Scleroderma
- Others (Migraine, etc.)
- By Route of Administration
- Oral
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top companies in Global Angiotensin Converting Enzymes (ACE) Inhibitors Market
- Novartis AG
- Pfizer Inc.
- Merck & Co.
- AstraZeneca
- Sanofi
- Boehringer Ingelheim
- GlaxoSmithKline
- Lupin Limited
- Torrent Pharmaceuticals Ltd.
- Reddy's Laboratories Ltd.
- Mylan
- Other Prominent Players
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Drugs
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Indication
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Route of Administration
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Distribution Channel
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Rising prevalence of hypertension
- Growing Research and Development Activities
- Increasing Awareness of Cardiovascular Health
- Restraints
- Patent Expirations
- Side Effects and Safety Concerns
- Side Effects and Safety Concerns
- Opportunities
- Drivers
- Increasing Awareness of Cardiovascular Health
- Personalized medicine
- Combination therapies
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Benazepril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Perindopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Trandfolapril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Captopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Enalapril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Lisinopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Others (Ramipril, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
5. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Indication, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
- Coronary Artery Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
- Heart Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
- Chronic Kidney Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn )
- Scleroderma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
- Others (Migraine, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
6. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Route of Administration, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
7. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
8. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (USD Mn)
- GCC
- Israel
- North Africa
- Central Africa
- Rest of Middle East & Africa
9. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Torrent Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
